Progress of tolvaptan in treatment of patients with autosomal dominant polycystic kidney disease
- VernacularTitle:托伐普坦治疗常染色体显性多囊性肾病患者的研究进展
- Author:
Yufa LIU
;
Guangxin CHEN
;
Naxin LIU
;
Lijun SU
- Publication Type:Journal Article
- Keywords:
tolvaptan;
autosomal dominant polycystic kidney disease;
progress
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;37(7):184-186
- CountryChina
- Language:Chinese
-
Abstract:
Databases of PubMed,CNKI,ScienceDirect and Wanfang were searched,and the literatures were selected from 1990 to 2014,to review the studies of tolvaptan on autosomal dominant polycystic kidney disease(ADPKD).ADPKD is a chronic progressive disease which significantly enhance the economy burden and death rate.No specific drug can be used to treat or prevent the progress of ADPKD.Tolvaptan applicated in early phase could prolong the progress of ADPKD,but with frequent and serious adverse events.
